The effects of COVID-19 infection on neurological health are becoming more apparent. A new study reveals COVID-19 can predispose people to irreversible neurological conditions, accelerate brain aging, and increase the risk of stroke and brain bleeds.
A novel helmet that generates a noninvasive oscillating magnetic field was able to reduce tumor mass by 31% in a glioblastoma brain cancer patient.
Researchers have identified acute transverse myelitis (ATM) in a number of COVID-19 patients. ATM, which is marked by inflammation of the spinal cord, is a rare neurological disorder that can lead to spinal cord lesions, paralysis, and bowel dysfunction.
MP-Pt(IV), a second generation prodrug appears to have curative properties against glioblastoma when coupled with chemotherapy in mouse models.
Researchers conducting a clinical trial of Remdesivir to treat coronavirus report the drug appears to be promising. The drug, initially designed to treat Ebola, is well tolerated, and patients treated with the drug are showing signs of recovery. Early indications suggest Remdesivir could stave off the need for intubating patients suffering from COVID-19.
On Saturday, the FDA approved Houston Methodist to conduct transfused plasma therapy for the treatment of COVID-19. The plasma will be donated from recovered COVID-19 patients and transfused into those critically ill with the virus. Researchers have already begun recruiting donors in the Houston area who have recovered from coronavirus. The first donor was a patient in the Houston Metropolitan area who has been in good health for two weeks following COVID-19 infection.
OCIAD1, a protein commonly associated with ovarian cancer, contributes to neurodegeneration in Alzheimer's disease by impairing mitochondrial function, leading to synaptic damage and neural vulnerability.
A compound used to treat leukemia shows promise in preventing breast cancer cells from metastasizing in the brain.
A major finding from researchers at Houston Methodist reveals a significant number of people diagnosed with schizophrenia or bipolar disorder may actually have a treatable immune system disorder. The condition causes NMDA receptors to stop functioning properly and can result in symptoms commonly associated with neuropsychiatric disorders.